The latest report titled “Global Pharmacovigilance Market” published by Emergen Research is projected to register a significant growth rate during the forecast period from 2024 to 2034. The Market Intelligence Report provides a complete overview of the Pharmacovigilance market along with details on the competitive landscape and profiles of the key players operating in this business. Our analyst team evaluates many other important aspects of the market, including historical market trends, estimated growth rates, revenue generation, production capacity, pricing structure, and key market drivers, opportunities, challenges, and constraints.
The latest research report offers an accurate study of the Pharmacovigilance industry and highlights key factors such as import/export analysis, production and consumption rates, distribution channels, and consumer base in key regions of the global market. This report further explores key facts and figures related to current market conditions and provides an industry-validated database for companies looking to invest in the market.
Additionally, the report provides actionable insights that help readers identify key opportunities and challenges faced in the broad competitive landscape of the Pharmacovigilance market. These insights also help formulate lucrative business expansion strategies to gain a competitive edge in the market.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/81
The global Pharmacovigilance Market size was valued at approximately USD 7.9 billion in 2024 and is projected to reach USD 21.4 billion by 2034, expanding at a CAGR of 10.5% over the forecast period. Growth in the market is fueled by the increase in the occurrence of adverse drug reactions (ADRs), growing regulatory compliance, and the increasing number of clinical trials and post-marketing surveillance.
The increase in global use of drugs—particularly driven by growth in chronic diseases, cancer treatments, and sophisticated biologics—has created demands for more effective systems to identify, evaluate, and prevent drug adverse events. Regulatory bodies such as the FDA (USA), EMA (EU), and CDSCO (India) are implementing stricter pharmacovigilance regulations, compelling pharmaceutical companies and CROs to make investments in internal capabilities as well as outsourced solutions.
Advances in technology, such as AI and big data analytics, are facilitating real-time ADR monitoring and increasing signal detection abilities. In addition, electronic health records (EHRs) and mobile health reporting technologies are enhancing the collection of real-world evidence (RWE) to facilitate active pharmacovigilance.
Contract outsourcing keeps growing, especially among smaller to mid-sized pharmaceutical firms looking for cost-effectiveness and regulatory knowledge. At the same time, growth of phase IV post-marketing research—mandated to track long-term drug safety—is playing a large role in driving market demand.
In spite of healthy growth opportunities, issues like underreporting of ADRs, lack of standardized global rules, and data standardization are still possible brakes on full-scale acceptance, particularly in low- and middle-income nations.
Competitive Landscape:
The latest study provides an insightful analysis of the broad competitive landscape of the global Pharmacovigilance market, emphasizing the key market rivals and their company profiles. A wide array of strategic initiatives, such as new business deals, mergers & acquisitions, collaborations, joint ventures, technological upgradation, and recent product launches, undertaken by these companies has been discussed in the report.
Rising Regulatory Pressure and Global Focus on Drug Safety Fuel Pharmacovigilance Demand
One of the major factors driving the pharmacovigilance market demand is the growing worldwide concern for drug safety and the strengthening of regulatory requirements globally. Health organizations like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Japan's PMDA, and so forth are requiring more robust pharmacovigilance processes during the entire lifecycle of a drug, especially after approval.
With growing pharma pipelines featuring increased numbers of biologics, personalized medicines, and new drug classes, regulators are requiring real-world safety data and ongoing adverse event monitoring. These demands have raised the stakes for pharmacovigilance not just in clinical trials but also in post-marketing surveillance (Phase IV), where long-term effects and unusual side effects are better captured.
They are also introducing stronger pharmacovigilance regulations, led by WHO and regional harmonization (e.g., ICH, CIOMS). This global harmonization is raising the compliance cost for pharma firms, leading to the outsourcing of pharmacovigilance functions to expert CROs and service providers.
In addition, the move towards electronic capture of data, patient-focused safety reporting through mobile devices, and EHR and claims data integration is supporting automated detection of signals and risk reduction measures, spurring the need for technologically sophisticated pharmacovigilance platforms.
Overall, the worldwide drive towards patient safety, regulatory adherence, and real-time safety information is an imperative driver fuelling the pharmacovigilance industry.
Emergen Research is Offering a full report (Grab a Copy Now) @ https://www.emergenresearch.com/industry-report/pharmacovigilance-market
Market Segmentation:
The report bifurcates the Pharmacovigilance market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.
Leading pharmacovigilance market manufacturers, are concentrating their competitive strategies around AI-powered signal detection, real-time data integration, regulatory harmonization, and service scalability across the globe. These strategies attest to increasing demand for compliant and cost-effective post-marketing surveillance solutions in the complex biologics, personalized therapies, and speeded-up drug approvals era.
A key strategy is the harmonization of AI and machine learning to improve AE signal detection, causality analysis, and predictive analytics. These technologies minimize manual workload, enhance case triaging, and facilitate quicker pharmacovigilance reporting.
Leading providers are creating end-to-end PV platforms that integrate EHRs, eCRFs, and sources of RWD—enabling continuous, automated monitoring throughout the product life cycle. Cloud-based systems are gaining traction to support remote pharmacovigilance activities and worldwide regulatory compliance.
Outsourcing alliances are growing very fast, with the pharma industry offloading PV activities to full-service CROs, BPOs, and specialty safety providers as a means of saving costs and improving flexibility. Mid-size biopharma companies and generics players are especially driving this trend.
Global harmonization activities are defining another strategic initiative, with major players aligning services to FDA's FAERS, EMA's EudraVigilance, and WHO's VigiBase processes. Local regulatory conformity is given prominence in emerging markets like India, China, and Brazil.
Finally, firms are also investing in natural language processing (NLP) solutions to extract and process AEs from unstructured channels—social media, patient forums, and call centers—enriching signal detection in consumerist environments.
Some major players included in the global pharmacovigilance market report are:
- Accenture
- Cognizant
- Laboratory Corporation of America Holdings
- IBM
- ArisGlobal
- ICON plc
- Capgemini
- Wipro
- IQVIA
- Parexel International Corporation
Our goal at Emergen Research is to empower businesses with the knowledge and insights necessary to make informed decisions and thrive in today's dynamic business landscape. Our market research content is designed to equip professionals and organizations with comprehensive analyses, actionable recommendations, and a competitive edge to achieve their growth objectives.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/81
The global Pharmacovigilance Market size was valued at approximately USD 7.9 billion in 2024 and is projected to reach USD 21.4 billion by 2034, expanding at a CAGR of 10.5% over the forecast period. Growth in the market is fueled by the increase in the occurrence of adverse drug reactions (ADRs), growing regulatory compliance, and the increasing number of clinical trials and post-marketing surveillance.
The increase in global use of drugs—particularly driven by growth in chronic diseases, cancer treatments, and sophisticated biologics—has created demands for more effective systems to identify, evaluate, and prevent drug adverse events. Regulatory bodies such as the FDA (USA), EMA (EU), and CDSCO (India) are implementing stricter pharmacovigilance regulations, compelling pharmaceutical companies and CROs to make investments in internal capabilities as well as outsourced solutions.
Advances in technology, such as AI and big data analytics, are facilitating real-time ADR monitoring and increasing signal detection abilities. In addition, electronic health records (EHRs) and mobile health reporting technologies are enhancing the collection of real-world evidence (RWE) to facilitate active pharmacovigilance.
Contract outsourcing keeps growing, especially among smaller to mid-sized pharmaceutical firms looking for cost-effectiveness and regulatory knowledge. At the same time, growth of phase IV post-marketing research—mandated to track long-term drug safety—is playing a large role in driving market demand.
In spite of healthy growth opportunities, issues like underreporting of ADRs, lack of standardized global rules, and data standardization are still possible brakes on full-scale acceptance, particularly in low- and middle-income nations.
Target Audience of the Global Pharmacovigilance Market Report:
- Key Market Players
- Investors
- Venture capitalists
- Small- and medium-sized and large enterprises
- Third-party knowledge providers
- Value-Added Resellers (VARs)
- Global market producers, distributors, traders, and suppliers
- Research organizations, consulting companies, and various alliances interested in this sector
- Government bodies, independent regulatory authorities, and policymakers
Key features and benefits of Emergen Research's market research content include:
- Comprehensive Analysis: Each piece of content is meticulously researched and provides a detailed analysis of market trends, competitive landscape, consumer behavior, and emerging opportunities. Businesses can leverage this information to identify untapped markets, devise effective marketing strategies, and make data-driven decisions.
- Actionable Recommendations: The market research content provides practical insights and actionable recommendations to help businesses enhance their products, services, and overall customer experience. These recommendations are tailored to the specific needs and challenges of each industry, allowing companies to implement strategies that drive growth and profitability.
- Expert Insights: Emergen Research's team of industry experts and analysts contribute their in-depth knowledge and expertise to every piece of content. Their insights shed light on industry-specific challenges, best practices, and emerging trends, helping businesses stay ahead of the competition and seize new opportunities.
- Timely Updates: The market research content is regularly updated to reflect the latest market trends and dynamics. Subscribers will have access to the most up-to-date information, enabling them to adapt their strategies and stay relevant in today's rapidly evolving business environment.
The global Pharmacovigilance Market size was valued at approximately USD 7.9 billion in 2024 and is projected to reach USD 21.4 billion by 2034, expanding at a CAGR of 10.5% over the forecast period. Growth in the market is fueled by the increase in the occurrence of adverse drug reactions (ADRs), growing regulatory compliance, and the increasing number of clinical trials and post-marketing surveillance.
The increase in global use of drugs—particularly driven by growth in chronic diseases, cancer treatments, and sophisticated biologics—has created demands for more effective systems to identify, evaluate, and prevent drug adverse events. Regulatory bodies such as the FDA (USA), EMA (EU), and CDSCO (India) are implementing stricter pharmacovigilance regulations, compelling pharmaceutical companies and CROs to make investments in internal capabilities as well as outsourced solutions.
Advances in technology, such as AI and big data analytics, are facilitating real-time ADR monitoring and increasing signal detection abilities. In addition, electronic health records (EHRs) and mobile health reporting technologies are enhancing the collection of real-world evidence (RWE) to facilitate active pharmacovigilance.
Contract outsourcing keeps growing, especially among smaller to mid-sized pharmaceutical firms looking for cost-effectiveness and regulatory knowledge. At the same time, growth of phase IV post-marketing research—mandated to track long-term drug safety—is playing a large role in driving market demand.
In spite of healthy growth opportunities, issues like underreporting of ADRs, lack of standardized global rules, and data standardization are still possible brakes on full-scale acceptance, particularly in low- and middle-income nations.
Additional information offered by the report:
- Along with a complete overview of the global Pharmacovigilance market, the report provides detailed scrutiny of the diverse market trends observed on both regional and global levels.
- The report elaborates on the global Pharmacovigilance market size and share governed by the major geographies.
- It performs a precise market growth forecast analysis, cost analysis, and a study of the micro- and macro-economic indicators.
- It further presents a detailed description of the company profiles of the key market contenders.
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com